Valproic acid binding to human serum and human placenta in vitro.
The binding characteristics of the antiepileptic agent and teratogen valproic acid for human serum and human placenta were investigated utilizing equilibrium dialysis of the drugs in serum and in homogenates of whole placenta so that the transplacental transfer of the drug could be better defined. A low-capacity, high-affinity binder and a high-capacity, low-affinity binder for valproic acid were found in serum. However, there was only minimal, nonspecific binding of the drug to placenta. It appears that transplacental transfer of valproic acid is not mediated by binding to placenta. It is likely that such transfer occurs by passive diffusion, which may be facilitated by the lipophilicity of the drug and by development of a pH gradient across the placenta. These findings indicate that the placenta is not a depot for valproic acid.
Bailey
David N
DN
Division of Laboratory Medicine, Department of Pathology, University of California, San Diego, San Diego, California 92103-8320, USA. dnbailey@ucsd.edu
Briggs
John R
JR
D001798:Blood Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D011485:Protein Binding; D014635:Valproic Acid / Q000378:metabolism*
D001798:Blood Proteins; D014635:Valproic Acid